Icure Pharmaceutical Incorporation

As of June 30, 2026, Icure Pharmaceutical Incorporation has 37.37M shares outstanding.

As of June 30, 2026, Icure Pharmaceutical Incorporation maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 96.73, indicating elevated leverage, while an interest coverage ratio of 1.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Icure Pharmaceutical Incorporation posted a negative return on equity (ROE) of -51.34, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.15, reflecting losses generated across the asset base. The company generates approximately 367.83M in revenue per employee across its workforce of 287.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.21 indicates how many times Icure Pharmaceutical Incorporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Icure Pharmaceutical Incorporation recorded 2.48M in income tax expense. The company reported a pretax loss of -21.42B and -20.02B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Icure Pharmaceutical Incorporation's stock has declined approximately 34.98% over the past 52 weeks. The 50-day moving average sits at 1,761.40, while the 200-day moving average is 1,805.44.

Over the twelve months ended June 30, 2026, Icure Pharmaceutical Incorporation generated 105.84B in revenue and converted that into -20.02B in net income, yielding earnings per share of -572.48. EBITDA reached 2.63B, while operating income came in at -2.32B.

As of June 30, 2026, Icure Pharmaceutical Incorporation holds 8.17B in cash and equivalents against 25.20B in total debt, resulting in a net debt position of 12.82B. Total book value stands at 28.10B, with working capital of -22.61B providing operational flexibility.

Icure Pharmaceutical Incorporation produced -2.34B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.50B in capital expenditures, free cash flow totaled -6.84B - equivalent to -182.70 per share.

Over the twelve months ended June 30, 2026, Icure Pharmaceutical Incorporation posted a gross margin of 8.15, reflecting its pricing power and cost economics. The operating margin of -2.19 and net profit margin of -18.91 provide insight into operational efficiency.

Icure Pharmaceutical Incorporation's most recent stock split took place on December 14, 2022 with a 5:6 split ratio.